The acute effect of chlorpromazine on body temperature in intensive care unit patients

Not Applicable

Completed

• Conditions: Adverse drug reaction; Anaesthesiology - Other anaesthesiology

• Registration Number: ACTRN12621000700831
• Lead Sponsor: Selcuk University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-07-29
• Study Start: 2021-06-08
• Last Update Posted: 14 June 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 63

Inclusion Criteria

After obtaining participants' informed consent, 63 patients, who were aged 18-85 years and stayed in ICU for at least 24 hours after admission will enroll in the study.

Exclusion Criteria

Schizophrenia, hyperthermia syndromes (e.g., malignant hyperthermia, neuroleptic malignant syndrome), endocrinal states which may cause hyperthermia, shock states (with lactic acid levels > 4 mmol), diagnosed hepatitis (with alanine aminotransferase levels more than twice the upper limit), chronic hepatic insufficiency, pregnancy, breastfeeding, use of medications (such as antibiotics, steroids, non-steroid anti inflammatory drugs, antipyretics, sedative-hypnotics, and anticonvulsants), and history of blood product transfusion or surgery within 24 hours will exclude from the study.

Study & Design

• Study Type: Observational
• Study Design: Not specified